Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mouse gut metagenome (410661)

ABSTRACT: Intestinal microbiota controls graft-versus-host disease independent of donor-host genetic disparity

PROVIDER: PRJNA980199 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24830000_1.fastq.gz	Fastqsanger.gz
	SRR24830000_2.fastq.gz	Fastqsanger.gz
	SRR24830100_1.fastq.gz	Fastqsanger.gz
	SRR24830100_2.fastq.gz	Fastqsanger.gz
	SRR24830200_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 934

Similar Datasets

Project description:Intestinal Microbiota Controls Graft-versus-Host Disease Independent of Donor-Host Genetic Disparity

| PRJNA979931 | ENA

Mus musculus

Project description:Donor T cells in ovarian graft versus host disease

| PRJNA321441 | ENA

Project description:Host NLRP6 exacerbates graft-versus-host disease independent of microbial diversity

| PRJNA491725 | ENA

The effect of LCN2 treatment on anti-inflammatory bone marrow derived macrophages

Project description:Allogeneic hematopoietic stem cell transplantation remains the most efficacious treatment for many hematological malignancies. However, its therapeutic potential is affected by the most prominent side effect graft versus host disease. Despite advances in the treatment of graft versus host disease in recent years, morbidity and mortality remains high, which requires the development of new treatment approaches. We therefore implemented mouse models to assess potential treatment options for graft versus host disease. In in vivo experiments, we had observed a protective effect of LCN2 on graft versus host disease of the gastrointestinal tract. We also observed higher numbers of anti-inflammatory macrophages in the intestinal tissues of these animals. Therefore, we aimed to determine potentially regulated genes in these cells by using an in vitro approach of LCN2-treated macrophages.

2024-01-24 | GSE226432 | GEO

mouse gut metagenome

Project description:Study of Intestinal microbiota in graft-versus-host disease

| PRJDB4167 | ENA

Proteomics and system biology identify an antitumoral signature following allogeneic donor lymphocyte injection

Project description:A protein signature that could identify graft-versus-tumor (GVT) activity without graft-versus-host disease (GVHD), would allow for customized treatment plans following hematopoietic cell transplantation (HCT). Using orthogonal three-dimensional intact-protein analysis system (IPAS) coupled with protein tagging and novel systems biology pipeline, we identified a signature of 49 proteins that are significantly increased in the plasma of HCT patients who received donor lymphocyte injection for tumor relapse and develop GVT without GVHD.

2017-05-03 | MSV000081057 | MassIVE

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Project description:This phase II trial studies how well cyclophosphamide works in preventing chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients with hematological malignancies. Giving chemotherapy and total-body irradiation before transplantation helps stop the growth of cancer cells and prevents the patient’s immune system from rejecting the donor’s stem cells. Healthy stem cells from a donor that are infused into the patient help the patient’s bone marrow make blood cells; red blood cells, white blood cells, and platelets. Sometimes, however, the transplanted donor cells can cause an immune response against the body’s normal cells, which is called graft-versus-host disease (GVHD). Giving cyclophosphamide after transplant may prevent this from happening or may make chronic GVHD less severe.

| 2112331 | ecrin-mdr-crc

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Project description:RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the esophagus, stomach, small intestine, or colon.

| 2005776 | ecrin-mdr-crc

Microbial Bile Acid Metabolism Shapes Effector T Cell Responses During Inflammation in Mouse and Human

Project description:To comprehensively investigate the effects of graft-versus-host disease on host metabolism, we carried out RNA-sequencing analysis of bulk liver and epithelial cell fractions of the small and large intestines of bone marrow of mice who received bone marrow (BM) only grafts and mice co-transferred with donor T cells (BMT).

2023-09-21 | GSE218343 | GEO

Microbiota dictate T cell clonal selection to augment graft-vs-host disease after stem cell transplantation

Project description:Allogeneic T cell expansion is the primary determinant of graft-versus-host disease (GVHD), and current dogma dictates that this is driven by histocompatibility antigen disparities between donor and recipient. This paradigm represents a closed genetic system within which donor T cells interact with peptide-MHC complexes, though clonal interrogation remains challenging due to the sparseness of the T cell repertoire. We developed a Bayesian model using donor and recipient TCR frequencies in murine stem cell transplant systems to define limited common expansion of T cell clones across genetically identical donor-recipient pairs. A subset of donor CD4 T cell clonotypes differentially expanded in identical recipients and were microbiota dependent. Microbiota-specific T cells augmented GVHD lethality and could target microbial antigen presented by gastrointestinal epithelium during an alloreactive response. The microbiota thus serves as a source of cognate antigen that contributes to clonotypic T cell expansion and the induction of GVHD independent of donor-recipient genetics.

2024-06-03 | GSE267178 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data